AnaptysBio, Inc. (NASDAQ:ANAB) Receives $41.45 Average Price Target from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $41.45.

ANAB has been the topic of several research reports. JPMorgan Chase & Co. cut their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research report on Thursday, December 19th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Wedbush restated an “outperform” rating and issued a $40.00 price target (down previously from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. Truist Financial dropped their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. Finally, Guggenheim decreased their target price on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 12th.

Insiders Place Their Bets

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction on Thursday, January 2nd. The shares were bought at an average price of $12.95 per share, with a total value of $86,065.70. Following the acquisition, the director now directly owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 33.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

Institutional investors and hedge funds have recently made changes to their positions in the company. FMR LLC boosted its holdings in AnaptysBio by 15.3% in the third quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after purchasing an additional 438,557 shares during the period. Frazier Life Sciences Management L.P. boosted its holdings in shares of AnaptysBio by 2.0% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock valued at $74,008,000 after buying an additional 43,598 shares during the period. Assenagon Asset Management S.A. grew its position in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock valued at $15,927,000 after buying an additional 168,813 shares during the last quarter. Geode Capital Management LLC raised its stake in AnaptysBio by 3.0% during the third quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company’s stock worth $15,594,000 after acquiring an additional 13,336 shares during the period. Finally, Jennison Associates LLC bought a new position in AnaptysBio in the third quarter worth about $8,874,000.

AnaptysBio Stock Performance

ANAB opened at $14.36 on Monday. AnaptysBio has a 1 year low of $12.51 and a 1 year high of $41.31. The firm has a 50 day moving average price of $18.97 and a 200 day moving average price of $28.30. The company has a market cap of $436.96 million, a PE ratio of -2.36 and a beta of -0.02.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.72) by $0.58. The company had revenue of $30.02 million during the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, sell-side analysts predict that AnaptysBio will post -6.02 earnings per share for the current year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.